Trading Biotechs

Pages

Home
Biotechs by market cap
Medical Device Manufacturers
Biotechs - alphabetical order
Healthcare IT
Diseases
Glossary

Tuesday, September 5, 2017

=XOMA (XOMA) : upgraded to Outperform at Wedbush

Posted by Eva S at 6:22 PM

Email This BlogThis!Share to X Share to Facebook Share to Pinterest

Labels: upgrades, XOMA Ltd. (XOMA)

No comments:

Interesting Websites

Endpoints News
Labiotech.eu
Fierce Biotech
STAT
Biotech & Pharma Patent News

Search This Blog

biotechs

Labels

10-year performance 2-month performance 2-year performance 2013 IPOs 2014 IPOs 2015 IPOs 2016 IPOs 2017 IPOs 2018 IPOs 2019 IPOs 2020 IPOs 2021 IPOs 4-month performance 5-year performance 7-month performance 8-month performance 8-year performance Abaxis (ABAX) Abbott Laboratories (ABT) AbbVie (ABBV) ABEO ABIO ABLX ABRAXANE Abreva ABUS ACAD Acceleron Pharma (XLRN) ACET Achaogen (AKAO) ACHN acne acne vulgaris ACOR acquisition targets ACRS ACRX Actavis (ACT) Acura (ACUR) acute myeloid leukemia (AML) Adamis Pharma (ADMP) ADAP Adcetris ADHD ADMA ADMS Aduro BioTech (ADRO) ADXS AEMD AERI Affymetrix (AFFX) age-related macular degeneration Agenus (AGEN) Agios (AGIO) AGRX AIDS drugs AIMT AKBA AKCA Akcea AKDA AKRO AKRX AKTX Albany Molecular Research (AMRI) Alcobra (ADHD) Alder Biopharmaceuticals (ALDR) Aldeyra Therapeutics (ALDX) ALDR Algeta Alis Allergan (AGN) ALLO Allos Therapeutics Alnylam (ALNY) Alopecia Areata ALR ALS ALXN Alzheimer’s disease AMAG Amarin (AMRN) Ambit Biosciences (AMBI) Amedica (AMDA) Amgen (AMGN) AMGN Amicus Therapeutics (FOLD) AMPE AMPH AMRN AMRX ANAB anabasum Anacor (ANAC) Anavex Life Sciences (AVXL) angioedema ANI Pharma (ANIP) ANIK anoro Antares (AIS) ANTH Anthera (ANTH) antibiotics antiviral research apalutamide ApoGraft APOP Applied Genetic Technologies (AGTC) APRI APVO Aquinox (AQXP) Aralez Pharmaceuticals (ARLZ) Aramchol Arbor Pharmaceuticals ARCT Ardea (RDEA) Ardelyx (ARDX) ARDM Arena (ARNA) ARGX Ariad (ARIA) ARQL Array Biopharma (ARRY) artificial lung ARWR ASND asthma AstraZeneca (AZN) ataluren athenahealth (ATHN) Athersys (ATHX) atopic dermatitis ATRA ATRS ATRX aTyr Pharma (LIFE) Aurigene Aurinia Pharma (AUPH) Auspex Pharmaceuticals (ASPX) autoimmune diseases Auxilium (AUXL) Avandia Avanir (AVNR) Avastin AVDL Aveo (AVEO) AVXS AXGN AXON AXSM AYTU AZEDRA bankruptcy bapineuzumab baricitinib Barron's BAX Baxter (BAX) Bayer Benlysta BGNE BHC big one-day drops big one-day pops BIIB Bio-Reference Labs (BRLI) BIOA Biocept (BIOC) BioCryst (BCRX) BioSante (BPAX) biotech IPOs biotechs to watch BioTelemetry (BEAT) Biotie Therapies (BITI) BIS BIVV bladder cancer bladder pain BLFS blockbuster drugs blood cancer BLPH bluebird bio (BLUE) BMRN BNTC BOLD bone marrow transplantation Boston Scientific (BSX) BPTH brain cancer breast cancer Breethe Breo Ellipta brexanolone Bristol-Myers Squibb (BMY) British biotechs brontictuzumab BTX CABA Cabiralizumab Cabometyx cabozantinib CABP Cadence (CADX) Calithera Biosciences (CALA) cancer cancer diagnostics Cancer Genetics (CGIX) cancer testing cannabidiol (CBD) CAPR CAR T-cell therapies CARA CASC CASI CATB CBAY CBIO CCXI CDNA CDXC CDXS Celera (CRA) CELG Cell Therapeutics (CTIC) cell therapies Celladon (CLDN) Celldex Therapeutics (CLDX) Celltrion Cemiplimab Cempra (CEMP) central nervous system (CNS) diseases CEO pay Cephalon (CEPH) CERC Cerner (CERN) Cerus (CERS) cervical cancer CGON chemotherapy Chimerix (CMRX) CHMP cholesterol drugs Citron Research CLBR clear cell renal cell carcinoma clinical hold by FDA clinical trial deaths clinical trial results clinical trials CLLS Clovis Oncology (CLVS) CNAT CNCE Coherus (CHRS) colitis collaborations Collegium Pharmaceutical (COLL) colorectal cancer Complete Response Letter (CRL) Compugen (CGEN) Concerta Contrave Copaxone COPD Coronado Biosciences (CNDO) coronavirus Coversin COVID-19 CPRX CRBP Critical Limb Ischemia Crohn's disease CTRV CTXR Cubist Pharmaceuticals (CBST) Cullgen CUR Curis (CRIS) Cyclacel Pharmaceuticals (CYCC) cyclobenzaprine CYCN CYDY Cypress Bioscience (CYPB) cystic fibrosis CYTK CytomX Therapeutics (CTMX) dacomitinib Danish biotech DARE DAWN DBVT defibrillators demcizumab dementia DEPO depression DERM dermatitis dermatomyositis diabetes diabetic macular edema Dicerna (DRNA) Dicerna Pharma Dilaudid-HP Dipexium Pharmaceuticals (DPRX) disappointing trial results DMPI DNDN DOVA downside guidance Dravet syndrome DRRX drug prices drug research drug-related deaths Dry Eye Disease DTIL duchenne muscular dystrophy (dmd) Dupixent durvalumab Dutch IPOs duvelisib DVAX dystrophic epidermolysis bullosa Eagle Pharmaceuticals (EGRX) earnings EBS eczema EDIT Egalet (EGLT) Eisai Elan (ELN) Eleven Biotherapeutics (EBIO) Eli Lilly (LLY) Emergent BioSolutions (EBS) emicizumab Endo International (ENDP) Endocyte (ECYT) enobosarm ENTA Entrectinib Enzymotec (ENZY) epilepsy epinephrine Epizyme (EPZM) EQ Eravacycline Esbriet EscharEx Esperion (ESPR) EVOK executive reshuffles Exelixis (EXEL) eye diseases EYEG Fabry disease failed trials Fanapt Fanaptum Fast Track designation FBRX FDA approval FDA breakthrough designation FDA investigations FDA NDA FDA Priority Review FDA rejections FDA reversals FDA reviews FDA warnings FDRR FGEN Five Prime Therapeutics (FPRX) Flexion Therapeutics (FLXN) FLKS FLXN Foamix (FOMX) FOLOTYN Forest Laboratories (FRX) Fragile X syndrome fraud French biotechs Fresenius Frutarom FULC Furiex Pharmaceuticals (FURX) FUSILEV ga101 Galapagos (GLPG) Galectin Therapeutics (GALT) Galena Biopharma (GALE) Gaucher disease GBT GEMP gene editing gene therapies Genentech generic drugs Genocea Biosciences (GNCA) Genzyme (GENZ) German biotechs Geron (GERN) GILD Gilead Sciences (GILD) Gimoti glaucoma GlaxoSmithKline GlaxoSmithKline (GSK) GLMD GLYC GMS Tenshi GOCOVRI Grail great long trades GSK GTHX GTx (GTXI) GWPH Halozyme Therapeutics (HALO) Harvoni healthcare IT Heat Biologics (HTBX) hemophilia B hepatitis B hepatitis C Heplisav high cholesterol high cost of drugs HITK HIV HIV vaccine Hodgkin lymphoma Horizon Pharma (HZNP) Hospira (HSP) HPV HRTX HSTO Human Genome Sciences (HGSI) Humira Huntington's disease hypercholesterolemia IBB iBio (IBIO) ibrutinib IBS-C Iclusig ICPT Idera Pharmaceuticals (IDRA) IDIX Illumina (ILMN) IMDZ imetelstat IMGN IMMP Immunomedics (IMMU) immunotherapies immunotherapy immunotherapy drugs IMMY IMNP impulsive aggression (IA) Incyte (INCY) Infinity (INFI) Ingrezza initial public offering (IPO) INO Inogen (INGN) insider buys insider trading INSM insomnia insulin drugs INSYS Therapeutics (INSY) InterMune (ITMN) Intuitive Surgical (ISRG) INVA INVELTYS inVentiv Health (VTIV) Ionis Pharma (IONS) IOVA ipafricept IPCI Ipsen (IPSEY) IPXL irritable bowel syndrome (IBS) IRWD Isis (ISIS) Israeli biotechs Israeli IPOs ITCI ITEK Janssen Janssen-Cilag JAZZ JNCE JNJ Johnson & Johnson (JNJ) Juno Therapeutics (JUNO) KALA KALV Kamada (KMDA) Karyopharm Therapeutics (KPTI) KDMN Keryx (KERX) Keytruda kidney cancer kidney disease Kindred Biosciences (KIN) King (KG) King Pharmaceuticals (KG) KITE KKR KMPH knee pain KRYS KTOV KURA KYMR Kymriah Kyprolis lasmiditan lawsuits lemtrada Lennox-Gastaut syndrome leukemia Lexicon Pharma (LXRX) liability suits liposarcoma liver cancer liver diseases LJPC lorcaserin low T drugs LOXO LPCN lung cancer lung disease lupus lupus nephritis (LN) Lusduna luspatercept Luxturna lymphatic cancer lymphoma MacroGenics (MGNX) major depressive disorder (MDD) MAKO Surgical (MAKO) Mallinckrodt (MNK) MannKind (MNKD) marginal zone lymphoma (MZL) Marina Biotech (MRNA) MARQIBO Maryland biotechs MASH MASLD MBRX MBVX MDGL MDXG medical device IPOs Medicis Medivation (MDVN) MediWound (MDWD) Medtronic (MDT) melanoma menopause Merck (MRK) mergers & acquisitions Merrimack (MACK) mesothelioma metabolic disorders MGEN MGNX migalastat migraine Minerva Neurosciences (NERV) Mitsubishi Tanabe Pharma MNLO MNOV MNTA mongersen MOR most shorted MREO MRNA MRNS MRTX MT-3724 MTEM multiple myeloma multiple sclerosis muscular dystrophy myasthenia gravis (MG) MYL MYOK Myriad Genetics (MYGN) name changes NantHealth (NH) narcolepsy NASDAQ NASH NBRV NCNA NDAs NDRM negative trial results NEOS NEOT neratinib NERV net outflows Netherlands biotechs Neurocrine Biosciences (NBIX) New Drug Application new drugs Nexavar NIAGEN Nivalis Therapeutics (NVLS) nivolumab NK NKTR NKTR-214 NLNK non-alcoholic fatty liver disease (NAFLD) Novartis (NVS) NOVN Novo Nordisk (NVO) NRX NSRGY NSTG NTLA NVAX NVCR NVIV NYSE Ocaliva OCGN Ocular Therapeutix (OCUL) OGEN OHR Pharmaceutical (OHRP) omaveloxolon OMED Omeros (OMER) Oncobiologics (ONS) ONCS ONTX Onyx (ONXX) Opana ER Opdivo Ophthotech (OPHT) opioid pain killers OPK OPNT oral insulin Orexigen Therapeutics (OREX) ORMP Orphan Drug Designation (ODD) osimertinib osteoarthritis osteoporosis OTIC ovarian cancer OVID OXiGENE (OXGN) Oxtellar Pacific Biosciences of California (PACB) painkillers pancreatic cancer Paratek (PRTK) Parkinson's patents patisiran Paxil PBMD PCRX PDLI peanut allergy perampanel Peregrine (PPHM) Perrigo (PRGO) PETX PFE Pfizer (PFE) PGNX Pharmacyclics (PCYC) Piper Jaffray PIRS PLX pneumonia Pompe disease POSIMIR positive trial results Poziotinib Praluent Prana Biotechnology (PRAN) PRINTAA PRNB prostate cancer Prothena (PRTA) PRQR psoriasis PSTI PTC Therapeutics (PTCT) PTCL PTGX PTI PTI-125 PTIE PTLA PTN PTSD PTX PULM pulmonary arterial hypertension (PAH) pulmonary fibrosis Puma Biotechnology (PBYI) PZRX QDEL Qnexa Qsymia Questcor (QCOR) QURE Radius Health (RDUS) ralinepag Ramaswamy RAPIVAB Raptor (RPTP) rare diseases RARX RDHL Regado Biosciences Regenerative Medicine Advanced Therapy (RMAT) Regeneron (REGN) renal cell carcinoma (RCC) Repatha REPL Repligen (RGEN) Repros Therapeutics (RPRX) reproxalap Resolaris respiratory virus Restasis RETA Rett Syndrome Revance Therapeutics (RVNC) reverse mergers reverse stock splits Revlimid Rexahn (RNN) RGNX rheumatoid arthritis Rhopressa Rigel (RIGL) RoACTEMRA Roche (RHHBY) Rocket ROKA roxadustat Roxane Laboratories Rubraca RXDX SAGE Therapeutics (SAGE) sales growth SAVA Savient (SVNT) SBBP schizophrenia SCLN SCMP secondary offerings Seres Therapeutics (MCRB) SGEN SGMO Shanghai Fosun Pharmaceutical Shire (SHPG) sickle cell disease (SCD) SINUVA sitravatinib skin cancer skin diseases sleep apnea SLXP smallpox SNGX SNNA SNSS SNY sofosbuvir solanezumab Soliqua Soliris sotagliflozin Sovaldi Spark Therapeutics (ONCE) Spectrum (SPPI) spinoffs SpringWorks SRNE SRPT SRRA stem cells stock delisting stress urinary incontinence (SUI) Stryker (SYK) Sun Pharma Sunshine Heart (SSH) SUPN suspended trials Suvorexant SYBX Symtuza Synacthen Syndax Pharmaceuticals (SNDX) Syngeva BioPharma (GEVA) Synthetics Biologics (SYN) Tabelecleucel Takeda takeover candidates tarextumab Targacept (TRGT) Tenapanor TESARO (TSRO) Teva (TEVA) TGTX Theravance (THRX) THLD thyroid cancer ticker changes tisagenlecleucel TKAI TKMR TMO TNDM TNXP TOCA Tonmya TRACON Pharmaceuticals (TCON) Translarna (ataluren) Trastuzumab Trelegy Ellipta Tremfya TRISENOX TRVN TRXC TTOO TTPH tucatinib TXMD type X check TyrNovo UBX UCB UK IPOs ulcerative colitis (UC) Ultragenyx uniQure (QURE) upcoming IPOs upgrades upside guidance UTHR vantictumab Verenium (VRNM) Versartis (VSAR) Verzenio Vical (VICL) VIR ViroPharma (VPHM) VIRX Vital Therapies (VTL) VIVO Vivus (VVUS) VKTX VNDA Voclosporin Volanesorsen VRML VRNA VRTX VRX VSTM VYGR Vynfinit warnings weight loss weight loss drugs Wellbutrin XBiotech (XBIT) XenoPort (XNPT) XENT XLO XOMA Ltd. (XOMA) XON Xyosted Xyrem Yervoy Yescarta ZEVALIN ZFGN ZGNX Zika Zilretta Zimura ZIOP ZSAN ZYNE Zyprexa

Simple theme. Theme images by lucato. Powered by Blogger.

Pages

Tuesday, September 5, 2017

=XOMA (XOMA) : upgraded to Outperform at Wedbush

No comments:

Post a Comment